AssayIndex

AX-2026-041993

MOTS-c · 5 mg declared · AmbioPharm, Inc. · lot AMB-2601-N5360

PASSVERIFIED
Report ID
AX-2026-041993
Compound
MOTS-c
Compound class
Metabolic and mitochondrial peptides
Supplier
AMB — AmbioPharm, Inc.
Batch / lot
AMB-2601-N5360
Declared label claim
5mg
Laboratory
Nordanalyt Laboratories
Assay date
27 Jan 2026
Submitted
01 Feb 2026
Quarter
2026-Q1
Submitter
i.trevino
Sample provenance
Buyer-sourced
Section 1

Results

Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 35 min gradient, 214 nm99.70% area≥ 98.0PASS
Total impuritiesRP-HPLC, sum of reported peaks0.30% area≤ 2.0PASS
Largest single impurityRP-HPLC — Met1 sulfoxide (+16 Da)0.19% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula2173.0918DaNOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)2173.0898DaNOT TESTED
Mass accuracyobserved vs theoretical-0.9ppm± 15PASS
Total peptide contentby difference from the gravimetric mass balance89.00%w/wNOT TESTED
Target-compound contenttotal peptide content × purity88.73%w/wNOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen5.52mg5 mg declaredNOT TESTED
Recovered target peptidegross fill × target content4.898mg5 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim98.0%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate4.35%≤ 9.0PASS
Counter-ion (acetate)anion-exchange ion chromatography5.80%≤ 12.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.85%NOT TESTED
Endotoxinnot ordered on this submissionnot determined≤ 5.0NOT TESTED
Sterilitymembrane filtration, USP <71>, 14 dNo growth at 14 dno growthPASS
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intactwhite to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulatesclear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration5.662.5 – 8.0PASS
Retention time (observed)RP-HPLC, 35 min gradient12.05min12.02 ± 0.30 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.461.020.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²57,781≥ 20,000PASS
Resolution to nearest impurityvs des-Met1 (−131 Da)1.25no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

02279455968389118 MOTS-c12.05 min · 99.70 % 11.61 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 0510152025303540 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 57,781, and skew follows the reported asymmetry factor of 1.02. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.19 % impurity against a 99.70 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1MOTS-c — main peak12.054,845,72999.70
2Met1 sulfoxide (+16 Da)11.619,2350.19+15.995
3bis-sulfoxide (+32 Da)11.282,4300.05+31.990
4deamidated (+1 Da)11.701,9440.04+0.984
5des-Met1 (−131 Da)12.319720.02-131.040
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 2173.0918 Da, computed from C101H152N28O22S2. All ppm figures on this site are against monoisotopic values — see why that matters.

02550751003256751025137517252075 [M+2H]2+1087.55[M+1H]1+2174.10[M+3H]3+725.37 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 2173.0898 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
4+544.2802544.2797-0.00057.8
3+725.3712725.3705-0.000752.8
2+1087.55321087.5522-0.0010100.0
1+2174.09912174.0971-0.002056.9
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer4.35
Counter-ion (acetate)ion chromatography5.80
Residual solvent + inorganic residueestimated0.85
Total peptide contentby difference89.00
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.9099.70divergence +0.33 pp vs batch median
Total impurities (% area)0.100.30
Largest single impurity (% area)0.070.19
Water (%)2.74.35
Counter-ion (%)not stated5.80
Peptide content (%w/w)92.589.00
Endotoxin (EU/mg)0.50not determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Buyer-sourced
Evidentiary weight
Strongest available evidence in this index.
Chain of custody
Retail purchase → submitter (−20 °C, 20 d) → laboratory (courier, dry ice, 8 d) → assay.
Assay date
27 Jan 2026
Submitted to the index
01 Feb 2026
Laboratory
Nordanalyt Laboratories, Uppsala, Sweden
Method basis
35 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

lambda_280
If the nearest impurity carries an aromatic residue the parent lacks, dual-wavelength detection separates them without any chromatographic change at all. Cheap and underused.
c18_2p6
Doubling column length gains 40 % resolution and doubles the run. On a routine release method that trade is usually declined, and the certificate should say which method was run.
salt_exchange
Incomplete salt exchange leaves two counter-ions in the cake and only one gets measured. That is the commonest way a real balance acquires a genuine remainder.
Section 7

Related records

Same batch — lot AMB-2601-N5360 n=2

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041994AMB-2601-N5360Nordanalyt2026-Q199.435.13Buyer-sourced0PASS
Other recent MOTS-c records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042083HYBHYB-2606-D7858Medutest2026-Q399.932.02Buyer-sourced0PASS
AX-2026-042090HYBHYB-2606-D7858Janoshik2026-Q399.572.36Buyer-sourced1FAIL
AX-2026-042084HYBHYB-2606-D7858Janoshik2026-Q399.282.79107.3Buyer-sourced0PASS
AX-2026-042087HYBHYB-2606-D7858Janoshik2026-Q399.543.05Buyer-sourced0PASS
AX-2026-042085HYBHYB-2606-D7858Janoshik2026-Q399.512.31Buyer-sourced0PASS
AX-2026-042088HYBHYB-2606-D7858PeptideMeter2026-Q399.222.21Buyer-sourced0PASS
AX-2026-042086HYBHYB-2606-D7858Janoshik2026-Q399.933.02Buyer-sourced1MARGINAL
AX-2026-042081HYBHYB-2606-D7858Nordanalyt2026-Q399.683.3196.5Laboratory-retained0PASS
Other recent AMB records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042002SemaglutideAMB-2607-N6274VendorInvestigate2026-Q398.236.3797.1Buyer-sourced1MARGINAL
AX-2026-042012GHRP-6AMB-2603-S5667Janoshik2026-Q399.375.9088.8Laboratory-retained1MARGINAL
AX-2026-041974TirzepatideAMB-2603-C5112Nordanalyt2026-Q398.203.41Buyer-sourced0PASS
AX-2026-041975TirzepatideAMB-2603-C5112Medutest2026-Q397.883.45106.9Laboratory-retained0PASS
AX-2026-042005SemaglutideAMB-2607-N6274PeptideMeter2026-Q398.096.4898.6Buyer-sourced1MARGINAL
AX-2026-042008EpitalonAMB-2602-Y6433Janoshik2026-Q399.308.75105.1Buyer-sourced0PASS
AX-2026-042021TB-500AMB-2602-P5987VendorInvestigate2026-Q399.864.79101.4Buyer-sourced0PASS
AX-2026-042015GHRP-6AMB-2603-S5667Janoshik2026-Q399.546.4497.1Buyer-sourced0PASS